PRINCETON, N.J., June 28, 2011 /PRNewswire/ -- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA ...

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...

DaTscan (ioflupane I 123 injection; GE Healthcare) was found to improve a physician’s ability to definitively diagnose patients with dementia with Lewy bodies (DLB) and increase their confidence in ...

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...

DaTscan is a radiopharmaceutical imaging agent that works by binding to dopamine transporters (DaT) in the brain. A specific marker for DaT, DaTscan produces images that provide visual evidence based ...

DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain. The Food and Drug Administration (FDA) has expanded the approval of ...

ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug ...

Determining the specific type of dementia early in the diagnostic process can lead to more targeted treatments and better ...

(RTTNews) - GE Healthcare (GE) announced on Thursday that DaTscan was approved by FDA for use in patients with suspected Dementia with Lewy Bodies or DLB. DaTscan is a radiopharmaceutical imaging ...

(MENAFN- PR Newswire) SCOTTSDALE, Ariz., April 24, 2023 /PRNewswire/ -- SimonMed is proud to announce we will offer GE HealthCare's radiopharmaceutical diagnostic tracer, DaTscanTM nationally starting ...